top of page
EpiGeneer

Subsidiary of AdRegeneer

Silhouette of a couple running at sunset

We unlock recovery in Multiple Sclerosis

Our Mission

Myelin, Remyelination

Our Commitment

We are on a mission to restore what was lost. Helping patients regain movement, sensation and independence through regenerative therapies.

Solutions

Nervous System Repair

Our therapy transforms the landscape of nervous system regeneration therapies. By integrating advanced epigenetic modulation, we directly promote remyelination, restoring lost neural functions with precision and safety.

While current approaches to neurodegenerative diseases focus largely on managing inflammation, our therapy breaks new ground by reprogramming glial cells at the transcriptional level and activating key repair pathways controlled by epigenetic factors such as histone deacetylase 2 (HDAC2). This technology unlocks new therapeutic possibilities, minimizes side effects, and accelerates the translation of breakthrough science into effective, remyelination-focused treatments.

Epigenetic, recovery

Lesion

Repair

Advantages of Our Therapy

Picture 1.png

Restores Function, Epigenetic Precision, Low-Dose, High-Impact Treatment

Repair, not just relief, Targeted regeneration, Strong effect, Minimal dose​

Science

Innovative Methods

EpiGeneer is advancing a new era in nervous system regeneration by directly targeting remyelination. Our lead innovation centers on activating HDAC2 to promote myelin repair and restore neural function, going beyond conventional anti-inflammatory therapies. With our proprietary technology, we reprogram glial cells for repair at the transcriptional level, setting EpiGeneer apart in the field.

Our Milestones

Proven Success

Pre-Clinical

We have completed pre-clinical studies demonstrating the efficacy of our drug technologies on cell-based models and 4 different animal models

Publications

Our research has been published in highly recognized journals, expanding the impact of our findings within the scientific and biopharma communities

Production

We are excited to announce the start of GMP production and readiness for our minipig study, marking a key step forward in our partnership and drug development journey

Regulatory Milestone

Positive scientific advice from BfArM validating our clinical trial protocols

Strtegic Partnerships

We are engaged in ongoing discussions with leading transdermal patch companies and pharma companies to establish strategic partnerships and explore opportunities for joint investment

GMP Production

Clinical Trials

Go-to Market

Our Team

Scientific Advisory Board

bottom of page